| Literature DB >> 33604928 |
Qijian Ji1,2, Jiwei Hou3,4, Xueqing Yong5, Guangming Gong6, Mohd Muddassir7, Tianyu Tang8, Jinbing Xie8, Wenpei Fan9, Xiaoyuan Chen10.
Abstract
Inhibiting the myofibroblast differentiation of lung-resident mesenchymal stem cells (LR-MSCs) is a promising yet challenging approach for pulmonary fibrosis (PF) therapy. Here, micelles formed by a graft copolymer of multiple PEGs modified branched polyethylenimine are used for delivering runt-related transcription factor-1 (RUNX1) small interfering RNA (siRNA) (siRUNX1) to the lung, aiming to inhibit the myofibroblast differentiation of LR-MSCs. LR-MSC targeting is achieved by functionalizing the micelle surface with an anti-stem-cell antigen-1 antibody fragment (Fab'). Consequently, therapeutic benefits are obtained by successful suppression of myofibroblast differentiation of LR-MSCs in bleomycin-induced PF model mice treated with siRUNX1-loaded micelles. Furthermore, an excellent synergistic effect of PF therapy is achieved for this micelle system loaded siRUNX1 and glioma-associated oncogene homolog-1 (Gli1) small interfering RNA (siGli1), a traditional anti-PF siRNA of glioma-associated oncogene homolog-1. Hence, this work not only provides RUNX1 as a novel PF therapeutic target, but also as a promising dual siRNA-loaded nanocarrier system for the therapy of PF.Entities:
Keywords: lung-resident mesenchymal stem cells; micelles; pulmonary fibrosis; runt-related transcription factor 1; small interfering ribonucleic acid
Year: 2021 PMID: 33604928 DOI: 10.1002/adma.202007798
Source DB: PubMed Journal: Adv Mater ISSN: 0935-9648 Impact factor: 30.849